Lenalidomide-based maintenance therapy may be the most effective in myeloma

Continuous therapy with lenalidomide may lead to the greatest improvements in survival outcomes among patients with newly diagnosed multiple myeloma (NDMM) compared with other regimens in the maintenance setting, according to a study published in JAMA Oncology.1

Many agents have demonstrated efficacy as maintenance agents in patients with NDMM. Due to a lack of comparative studies, however, evidence supporting the overall superiority of one regimen over another is lacking.

For this meta-analysis, researchers evaluated the outcomes of 11 studies representing 5073 patients with NDMM and 8 different treatment regimens. The maintenance options evaluated were no maintenance/placebo, bortezomib plus prednisone, interferon, lenalidomide alone, lenalidomide plus prednisone, thalidomide alone, thalidomide plus bortezomib, and thalidomide plus interferon.

Read more: https://www.cancertherapyadvisor.com/multiple-myeloma/multiple-myeloma-lenalidomide-maintenance-therapy-effective/article/788589/